Roger, AlbertMalet, AlfonsMoreno, VictoriaParra, AntonioGutiérrez, DiegoLleonart, RamónMoreno, FranciscoValero, AntonioNavarro, BegoñaHinojosa, BelénJusticia, José L2023-02-082023-02-082020-01-08http://hdl.handle.net/10668/14927Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus® in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (penAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Dermatophagoides pteronyssinusadjuvantsallergic rhinitiseffectivenesshouse dust mitesreal-life clinical practicesafetysubcutaneous allergen immunotherapyAdjuvants, ImmunologicAdolescentAdultAgedAnimalsAntigens, DermatophagoidesDesensitization, ImmunologicFemaleHumansInjections, SubcutaneousMaleMiddle AgedNovobiocinProspective StudiesPyroglyphidaeRhinitis, AllergicTreatment OutcomeTyrosineYoung Adultresearch article31910695open access10.2217/imt-2019-02051750-7448https://www.futuremedicine.com/doi/pdf/10.2217/imt-2019-0205